Isolation of Hybridomas Producing Monoclonal Antibodies (MAbs) Inhibitory to Human CYP2J2
by
nih.govPosted
Fri 31 Oct 2003 4:00pm
Description of Invention:
Cytochromes P450 catalyze the NADPH-dependent oxidation of arachidonic acid to various eicosanoids found in several species. The eicosanoids are biosynthesized in numerous tissues including pancreas, intestine, kidney, heart, and lung where they are involved in many different biological activities.
...
Read on »
Chimeric Anti-human ROR1 Monoclonal Antibodies
by
nih.govPosted
Mon 23 Aug 2010 5:00pm
Description of Invention:
Available for licensing are mouse anti-human receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibodies (mAbs). ROR1 is a signature cell surface antigen for B-cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL) cells, two incurable B-cell malignancies that are n ...
Read on »
Monoclonal Antibodies
by
CancerTeam ..Posted
Sun 24 Aug 2008 1:49pm
ANNOUNCER: Non-Hogdkin's lymphoma, or NHL, is a white blood cell cancer of the lymphatic system. Over 50,000 new cases are expected to be diagnosed this year in the U.S. At a Gilda's club gathering in Chicago, lymphoma patients, and those who wanted to learn about the disease, found out about current treatment options.
LEO GORDON, MD: When we us ...
Read on »
Treating large bowel cancer with monoclonal antibodies
by
Dr. Anshu GuptaPosted
Tue 02 Jun 2009 4:39pm
Monoclonal antibodies are drugs that recognise and lock onto specific proteins (receptors) that are present in particular cancer cells.
Some cancer cells have parts known as e pidermal g rowth f actor r eceptors ( EGFRs ). When proteins in the body known as growth factors attach to these receptors, the cancer cell is stimulated to grow ...
Read on »
Agonistic Human Monoclonal Antibodies Against DR4
by
nih.govPosted
Mon 14 Mar 2011 8:00pm
Description of Invention:
The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and its functional receptors, DR4 and DR5, have been recognized as promising targets for cancer treatment. Therapeutics targeting TRAIL and its receptors are not only effective in killing many types of tumors but they also syne ...
Read on »
Monoclonal Antibodies for Rare Diseases
by
nih.govPosted
Wed 20 Jul 2011 8:00pm
Description of Invention:
Available for licensing are three monoclonal antibodies (mAb) that bind with high specificity and affinity to the tumor cell surface antigen tyrosine kinase-like orphan receptor 1 (ROR1). ROR1 is expressed in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), two incurable B-cell mali ...
Read on »
Monoclonal Antibodies That React With the Capsule of Bacillus anthracis
by
nih.govPosted
Sun 30 Aug 2009 5:00pm
Description of Invention:
Bacillus anthracis is the causative agent of anthrax and is surrounded by a polypeptide capsule of poly-gamma-D-glutamic acid (gammaDPGA). gammaDPGA is poorly immunogenic and has antiphagocytic properties. The bacterial capsule is essential for virulence. Antibodies to the capsule have been shown t ...
Read on »
Monoclonal Antibodies to the Tumor-Specific Antigen, Human ROR1
by
nih.govPosted
Thu 16 Aug 2012 8:00pm
Description of Invention:
B-cell chronic lymphocytic leukemia (B-CLL) is an incurable disease developed by more than 15,000 Americans each year and currently, there are no therapeutic monoclonal antibodies (mAbs) that specifically recognize B-CLL tumor cells. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a constit ...
Read on »
High-Affinity Rabbit Monoclonal Antibodies To Mesothelin for Treatment of Cancer
by
nih.govPosted
Wed 23 Jan 2013 7:00pm
Description of Invention:
Mesothelin is a cell surface protein that is highly expressed in aggressive cancers, such as malignant mesothelioma, ovarian cancer and pancreatic cancer. Because of this selective expression, mesothelin is an excellent candidate for targeted therapeutics, such as monoclonal antibodies (mAbs) and chi ...
Read on »
